Our pipeline of potential human therapeutic products continues to advance. We initiated a Phase II clinical trial of our MAXY-G34 product in breast cancer patients in June 2007. We expect to file an IND/CTA for our MAXY-VII product for hemophilia in the first half of 2008.

Behind these product candidates, Maxygen has a broad pipeline of other human therapeutics products that are in earlier stages of development. We believe these candidates will provide the basis for a steady stream of additional INDs in the coming years.

Protein Therapeutics pipeline

Return to Products